

9. Ohshima Y, Hanaoka H, Watanabe S, et al. Preparation and biological evaluation of 3-[⁷⁶Br]bromo- α -methyl-L-tyrosine, a novel tyrosine analog for positron emission tomography imaging of tumors. *Nucl Med Biol.* 2011;38:857–865.
10. Löfvqvist A, Sundin A, Ahlstrom H, Carlsson J, Lundqvist H. Pharmacokinetics and experimental PET imaging of a bromine-76-labeled monoclonal anti-CEA antibody. *J Nucl Med.* 1997;38:395–401.
11. Tomiyoshi K, Amed K, Muhammad S, et al. Synthesis of isomers of F-18-labelled amino acid radiopharmaceutical: position 2- and 3-L-F-18- α -methyltyrosine using a separation and purification system. *Nucl Med Commun.* 1997;18:169–175.
12. Watanabe S, Hanaoka H, Liang JX, Iida Y, Endo K, Ishioka NS. PET imaging of norepinephrine transporter-expressing tumors using ⁷⁶Br-meta-bromobenzylguanidine. *J Nucl Med.* 2010;51:1472–1479.
13. Kuga N, Shikano N, Takamura N, et al. Competitive displacement of serum protein binding of radiopharmaceuticals with amino acid infusion investigated with N-isopropyl-p-¹²³I-iodoamphetamine. *J Nucl Med.* 2009;50:1378–1383.
14. Khunweeraphong N, Nagamori S, Wiriyasermkul P, et al. Establishment of stable cell lines with high expression of heterodimers of human 4F2hc and human amino acid transporter LAT1 or LAT2 and delineation of their differential interaction with α -alkyl moieties. *J Pharmacol Sci.* 2012;119:368–380.
15. Lahoutte T, Mertens J, Cavelliers V, Franken PR, Everaert H, Bossuyt A. Comparative biodistribution of iodinated amino acids in rats: selection of the optimal analog for oncologic imaging outside the brain. *J Nucl Med.* 2003;44:1489–1494.
16. Yanagida O, Kanai Y, Chairoungdua A, et al. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. *Biochim Biophys Acta.* 2001;1514:291–302.
17. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? *Semin Cancer Biol.* 2005;15:254–266.
18. Pineda M, Fernandez E, Torrents D, et al. Identification of a membrane protein, LAT-2, that coexpresses with 4F2 heavy chain, an L-type amino acid transport activity with broad specificity for small and large zwitterionic amino acids. *J Biol Chem.* 1999;274:19738–19744.
19. Rossier G, Meier C, Bauch C, et al. LAT2, a new basolateral 4F2hc/CD98-associated amino acid transporter of kidney and intestine. *J Biol Chem.* 1999;274:34948–34954.
20. Wiriyasermkul P, Nagamori S, Tominaga H, et al. Transport of 3-fluoro-L- α -methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET. *J Nucl Med.* 2012;53:1253–1261.
21. Inoue T, Tomiyoshi K, Higuichi T, et al. Biodistribution studies on L-3-[fluorine-18]fluoro- α -methyl tyrosine: a potential tumor-detecting agent. *J Nucl Med.* 1998;39:663–667.
22. Essig A, Taggart JV. Competitive inhibition of renal transport of p-aminohippurate by other monosubstituted hippurates. *Am J Physiol.* 1960;199:509–512.
23. Wieland DM, Wu J, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH. Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with [¹³¹I]iodobenzylguanidine. *J Nucl Med.* 1980;21:349–353.
24. Inoue T, Koyama K, Oriuchi N, et al. Detection of malignant tumors: whole-body PET with fluorine 18 α -methyl tyrosine versus FDG—preliminary study. *Radiology.* 2001;220:54–62.
25. Inoue T, Shibasaki T, Oriuchi N, et al. ¹⁸F α -methyl tyrosine PET studies in patients with brain tumors. *J Nucl Med.* 1999;40:399–405.
26. Kaira K, Oriuchi N, Shimizu K, et al. Comparison of L-type amino acid transporter 1 expression and L-[3-¹⁸F]- α -methyl tyrosine uptake in outcome of non-small cell lung cancer. *Nucl Med Biol.* 2010;37:911–916.
27. Miyakubo M, Oriuchi N, Tsushima Y, et al. Diagnosis of maxillofacial tumor with L-3-[¹⁸F]-fluoro- α -methyltyrosine (FMT) PET: a comparative study with FDG-PET. *Ann Nucl Med.* 2007;21:129–135.

Erratum

In the article “Assessment of Tumorcidal Efficacy and Response to Treatment with ¹⁸F-FDG PET/CT After Intra-arterial Infusion with the Antiglycolytic Agent 3-Bromopyruvate in the VX2 Model of Liver Tumor,” by Liapi et al. (*J Nucl Med.* 2011;52:225–230), the surname of the eighth author should be Ganapathy-Kanniappan. The authors regret the error.